表 2.
新月体型IgA肾病队列倾向性评分匹配后患者信息
Demographic and clinical characteristics of 46 patients with crescentic IgA nephropathy after PSM
| Items | Total population (n=46) | PLEX+IS group (n=23) | IS group (n=23) | P |
| PSM, propensity score matching; PLEX, plasma exchange therapy; IS, immunosuppressants; RB, renal biopsy; ACEi/ARB, angiotensin, converting enzyme inhibitor/angiotensin receptor blocker; MAP, mean arterial pressure; Hb, hemoglobin; ESR, erythrocyte sedimentation rate; RBC, red blood cell; Scr, serum creatinine; eGFR, estimated glomerular filtration rate; Alb, albumin; CRP, C, reactive protein; Total crescents, cellular crescents + fibrocellular crescents + fibrous crescents. | ||||
| Age/years, x±s | 38±18 | 37±18 | 39±19 | 0.769 |
| Male/% | 31 (67.4) | 16 (69.6) | 15 (65.2) | 0.753 |
| Time of follow-up/months, M(P25, P75) | 7 (1，26) | 9 (3，27) | 2 (0，22) | 0.212 |
| Course of disease/months, M(P25, P75) | 2.0 (1.0，6.3) | 4.0 (1.0，12.0) | 2.0 (1.0，5.0) | 0.073 |
| Prodromic infection/% | 17 (37.0) | 9 (39.1) | 8 (34.8) | 0.760 |
| Auria or oligouria/% | 5 (10.9) | 3 (13.0) | 2 (8.7) | 0.639 |
| Gross hematuria/% | 12 (26.1) | 4 (17.4) | 8 (34.8) | 0.184 |
| Hypertension history/% | 34 (73.9) | 19 (82.6) | 15 (65.2) | 0.184 |
| Dialysis prior to RB/% | 13 (28.3) | 6 (26.1) | 7 (30.4) | 0.743 |
| ACEi/ARB use prior to RB/% | 9 (19.6) | 6 (26.1) | 3 (13.0) | 0.270 |
| Steroids use prior to RB/% | 16 (34.8) | 12 (52.2) | 4 (17.4) | 0.014 |
| IS use prior to RB/% | 7 (15.2) | 6 (26.1) | 1 (4.3) | 0.042 |
| MAP/mmHg, x±s | 110.3±11.7 | 109.9±12.2 | 110.7±11.4 | 0.813 |
| Hb/(g/L), x±s | 103.8±21.6 | 107.2±16.7 | 100.5±25.6 | 0.296 |
| ESR/(mm/h), M(P25, P75) | 45.4±22.2 | 45.7±21.9 | 44.4±24.8 | 0.901 |
| Urine RBC/(/μL), M(P25, P75) | 466.4 (141.8，1 390.5) | 554.4 (140.1，1 728.9) | 457.0 (134.0，1 000.0) | 0.733 |
| 24-hour proteinuria/g, M(P25, P75) | 7.0±3.6 | 7.4±3.4 | 6.6±3.8 | 0.502 |
| Scr/(μmol/L), M(P25, P75) | 377.6 (283.3，633.7) | 352.8 (309.0，522.3) | 451.0 (258.7，775.0) | 0.374 |
| eGFR/[mL/(min·1.73m2)], M(P25, P75) | 12.74 (7.27，18.85) | 14.30 (9.31，17.58) | 11.45 (5.59，20.79) | 0.318 |
| Alb/(g/L), M(P25, P75) | 28.3±5.6 | 27.8±5.5 | 28.7±5.8 | 0.627 |
| IgG/(g/L), M(P25, P75) | 7.12(5.74，10.30) | 7.13(5.71，10.42) | 6.41(5.00，10.01) | 0.849 |
| IgA/(g/L), M(P25, P75) | 2.86(2.04，3.54) | 2.79(1.70，3.69) | 3.00(2.13，3.45) | 0.107 |
| IgM/(g/L), M(P25, P75) | 0.75±0.32 | 0.76±0.34 | 0.74±0.31 | 0.864 |
| C3/(g/L), M(P25, P75) | 0.83±0.26 | 0.78±0.26 | 0.89±0.24 | 0.165 |
| C4/(g/L), M(P25, P75) | 0.26±0.09 | 0.25±0.08 | 0.27±0.11 | 0.525 |
| CRP/(g/L), M(P25, P75) | 6.68±7.15 | 6.89±6.50 | 6.28±8.58 | 0.823 |
| Global sclerosis/%, M(P25, P75) | 0(0，8.33) | 0(0，10.00) | 0(0，7.69) | 0.694 |
| Ischemic sclerosis/%, M(P25, P75) | 8.82±9.97 | 8.11±10.03 | 9.54±10.07 | 0.484 |
| Crescents/%, M(P25, P75) | 65.45±12.83 | 64.49±13.23 | 66.41±12.65 | 0.617 |
| Total crescents/%, M(P25, P75) | 71.08±13.00 | 71.03±14.04 | 71.12±12.20 | 0.981 |
| ACEi/ARB use post to RB, n(%) | 9 (19.6) | 6 (26.1) | 3 (13.0) | 0.270 |
| Steroids use post to RB, n(%) | 44 (95.7) | 23 (100.0) | 21 (91.3) | 0.153 |
| Steroid impulse post to RB, n(%) | 34 (73.9) | 17 (73.9) | 17 (73.9) | 1.000 |
| IS use post to RB, n(%) | 23 (51.1) | 13 (59.1) | 10 (43.5) | 0.295 |